Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23219286
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Analysis of the ERalpha germline PvuII marker in breast cancer risk.

González-Mancha R, Galán JJ, Crespo C, Iglesias Pérez L, González-Perez A, Morón FJ, Moreno Nogueira JA, Real LM, Pascual MH, Ruiz A, Royo JL.

Med Sci Monit. 2008 Mar;14(3):CR136-43.

PMID:
18301357
[PubMed - indexed for MEDLINE]
3.

Non-Hodgkin's lymphomas: introduction.

Moreno-Nogueira JA, Casas A, Iglesias Perez L, Andrev-Kern F.

Cancer Clin Trials. 1979 Spring;2(1):63-9. Review. No abstract available.

PMID:
391432
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk